CNM‑Au8 and Parkinson’s: What the New Gold Nanotherapy Study Really Means
Darla in the Desert: where the sun is hot, the science is complicated, and the patience melts before the ice does. CNM‑Au8 and Parkinson’s: What This New Study Actually Means Every now and then, a study pops up that makes the Parkinson’s community sit up a little straighter. CNM‑Au8 — a catalytic gold nanocrystal therapy — is one of those “wait, what is this shiny thing?” moments. A recent peer‑reviewed study looked at CNM‑Au8 in people with Parkinson’s disease and found something researchers call brain target engagement . Translation: the drug reached the brain and did something measurable, not just theoretical. In the REPAIR‑PD phase 2 trial, participants showed a 10.4% increase in the NAD⁺/NADH ratio after about 12 weeks. That’s a fancy way of saying the brain’s energy chemistry shifted in a direction scientists like to see. What Is NAD⁺? NAD⁺ is a molecule your cells use to make energy — think of it as the spark plug in your brain’s engine. Parkinson’s...